Back

Economic Burden and Return on Investment of Immunization Programs in Saudi Arabia: A Health Economic Evaluation

Alshahrani, A. M.; Ashour, A. m.

2026-04-17 public and global health
10.64898/2026.04.15.26350984 medRxiv
Show abstract

Background Vaccine-preventable diseases (VPDs) continue to impose a significant health and economic burden globally, despite advances in immunization programs. Narrower to the context of Saudi Arabia, the current literature consistently shows that the high vaccination coverage has had the primary impact of reducing disease incidence. Regardless, the broader economic impact of VPDs and the financial benefits of immunization remain important for policy evaluation within Saudi Arabia. Methods This study employed a model-based economic evaluation using a societal perspective in order to carry out an estimation of the economic burden of measles, influenza, and pneumococcal diseases. We utilized the Cost of Illness (COI) approach for the purpose of quantifying direct medical costs and indirect productivity losses. On the other hand, the Value of Statistical Life (VSL) approach helped in the estimation of the monetary value of mortality reduction. A comparative framework analyzed current vaccination coverage against a counterfactual no-vaccination scenario for the calculation of the return on investment (ROI). Results The estimated annual economic burden of the three selected VPDs in the absence of vaccination was USD 385 (95% CI: 315-460) million. Immunization programs generated substantial economic benefits, with total benefits estimated at USD 1085 (95% CI: 815-1360) million annually. The calculated ROI was 9.0 (95% CI: 6.8-11.3), essentially an indication that for each dollar invested in vaccination, there was multiple economic returns yielded. Sensitivity analyses confirmed the robustness of these findings. Conclusion Immunization programs in Saudi Arabia provide significant economic and public health benefits and for this reason, sustained investment in vaccination is fundamentally essential towards the reduction of disease burden, improve population health, and ultimately support long-term economic productivity.

Matching journals

The top 6 journals account for 50% of the predicted probability mass.

1
Vaccine
189 papers in training set
Top 0.1%
21.6%
2
Vaccines
196 papers in training set
Top 0.2%
9.7%
3
Frontiers in Public Health
140 papers in training set
Top 1.0%
6.1%
4
BMC Medicine
163 papers in training set
Top 0.7%
6.1%
5
The American Journal of Tropical Medicine and Hygiene
60 papers in training set
Top 0.7%
6.1%
6
PLOS ONE
4510 papers in training set
Top 30%
6.1%
50% of probability mass above
7
BMC Public Health
147 papers in training set
Top 1.0%
4.7%
8
Vaccine: X
19 papers in training set
Top 0.1%
3.4%
9
BMJ Global Health
98 papers in training set
Top 1.0%
3.4%
10
Scientific Reports
3102 papers in training set
Top 52%
2.0%
11
PLOS Global Public Health
293 papers in training set
Top 4%
1.6%
12
Travel Medicine and Infectious Disease
15 papers in training set
Top 0.3%
1.4%
13
Human Vaccines & Immunotherapeutics
25 papers in training set
Top 0.5%
1.4%
14
BMC Infectious Diseases
118 papers in training set
Top 4%
1.3%
15
JMIR Public Health and Surveillance
45 papers in training set
Top 3%
1.2%
16
Public Health
34 papers in training set
Top 1%
1.2%
17
Journal of Global Health
18 papers in training set
Top 0.4%
1.2%
18
International Journal of Infectious Diseases
126 papers in training set
Top 3%
0.9%
19
The Lancet Global Health
24 papers in training set
Top 1.0%
0.9%
20
PLOS Medicine
98 papers in training set
Top 4%
0.8%
21
BMJ Open
554 papers in training set
Top 13%
0.7%
22
Clinical Infectious Diseases
231 papers in training set
Top 5%
0.7%
23
Frontiers in Medicine
113 papers in training set
Top 7%
0.7%
24
Infectious Diseases of Poverty
10 papers in training set
Top 0.5%
0.7%
25
BMC Health Services Research
42 papers in training set
Top 2%
0.7%
26
PLOS Neglected Tropical Diseases
378 papers in training set
Top 6%
0.7%
27
Epidemiology and Infection
84 papers in training set
Top 4%
0.6%